BREAKING NEWS...

Patients aged 12 to under 18 saw clinically meaningful regrowth on the scalp, eyebrow, and eyelashes with both high-dose and low-dose treatment.

Join Shawn Bjorndal, PharmD, RPh, and Jesse McCullough, PharmD, for the first episode of Dispensing Leadership, a new podcast from Drug Topics® and RPhAlly.

Approximately 89.7% of patients taking CagriSema achieve the coprimary end point of weight loss of 5% or more compared with 30.3% on the placebo.

The Cut Hypertension Program operates in barbershops across the Bay Area in California. The program’s lead pharmacist joined us to discuss main themes and goals of the new initiative.

Investigators note that low itch and mild disease severity are maintained following a treatment-free interval of 80 days.

Researchers investigated the health benefits, utilization, harms, and costs associated with the use of alternative methods for colorectal cancer screening in Australia.